TGFβ inhibitors have so far shown significant efficacy in improving the cytotoxicity, and anti-tumor functions of NK cells, and future clinical trials combining TGFβ inhibitors with NK cell therapies are warranted. The gene discussed is TGFB1; the disease is neoplasm.